

# Should Familial Hypercholesterolaemia Be Included in the UK Newborn Whole Genome Sequencing Programme?

Steve E Humphries (PhD)<sup>1</sup>, Uma Ramaswami (MD)<sup>2</sup> & Neil Hopper (MB ChB)<sup>3</sup>

1. Centre for Cardiovascular Genetics, Rayne Building, 5 University Street, University College London, London, United Kingdom, WC1E 6JJ. [s.humphries@ucl.ac.uk](mailto:s.humphries@ucl.ac.uk)
2. Lysosomal Disorders Unit, Royal Free London NHS Foundation Trust, Royal Free Hospital, London, United Kingdom, NW3 2QG. [uma.ramaswami@nhs.net](mailto:uma.ramaswami@nhs.net)
3. South Tyneside and Sunderland NHS Foundation Trust, Sunderland Royal Hospital, Sunderland, United Kingdom. [n.hopper@nhs.net](mailto:n.hopper@nhs.net)

**Corresponding Author: Dr Uma Ramaswami**, Email [uma.ramaswami@nhs.net](mailto:uma.ramaswami@nhs.net). Lysosomal Disorders Unit, Royal Free London NHS Foundation Trust, Royal Free Hospital, London, NW3 2QG. ORCID number: 0000-0002-4703-7447

**Keywords:** Familial Hypercholesterolaemia; Whole Genome Sequencing; Newborn Genomes Programme; Healthy Lifestyle; LDL-Cholesterol Burden; Homozygous FH.

**4201 WORDS, 60 References, 1 Table and 1 Figure**

## Abstract

**Purpose of Review:** The UK National Health Service (NHS) has recently announced a Newborn Genomes Programme (NGP) to identify infants with treatable inherited disorders using whole genome sequencing (WGS). Here we address, for Familial Hypercholesterolaemia (FH), the four principles that must be met for inclusion of a disorder in the NGP.

**Recent Findings:** Principle A: There is strong evidence that the genetic variants causing FH can be reliably detected. Principle B: A high proportion of individuals who carry an FH-causing variant are likely to develop early heart disease if left undiagnosed and not offered appropriate treatment. Principle C: Early intervention has been shown to lead to substantially improved outcomes in children with FH. Principle D: The recommended interventions are equitably accessible for all.

**Summary:** FH meets all the Wilson and Jungner criteria for inclusion in a screening programme and it also meets all the four principles and therefore should be included in the Newborn Genomes Programme.

## Introduction

Familial Hypercholesterolaemia (FH) is an autosomal dominant monogenic condition (1) (that results in elevated Low Density Lipoprotein Cholesterol (LDL-C) from birth, with the long-term consequences of premature cardiovascular disease (CVD). It is now known that the prevalence of heterozygous FH (HeFH) worldwide is around 1 in 250 (2), and recent data from the UK BioBank study has indicated that the prevalence in the UK is ~1 in 290 (95% Confidence intervals 1 in 264-316), with a similar frequency found in individuals from the Indian sub-continent and of African origin (3). This suggests that ~193,000 people in England have HeFH, of whom current estimates are that only 7% have been diagnosed (4). In 2019 the NHS published a Long Term Plan (LTP) (4) which included the ambition to increase genetically diagnosed HeFH from 7% of the expected cases to 25% within five years. Increased genetic testing will enable the identification and treatment of those at highest genetic risk of premature CVD and sudden cardiac death.

Individuals likely to have HeFH can be identified by searching of General Practice (GP) electronic notes to flag those with elevated LDL-C, an approach which has been shown to be feasible and cost effective in the UK health system (5). Recently, the concept of 'Child-Parent Screening' (CPS) has been suggested (6) as an additional approach to address the challenges of FH identification, by using children as the entry point for screening. Modelling of national data has shown that universal screening of infants alongside adult GP case finding as a unified approach, would allow the NHS to reach its target of 25% in approximately seven years and provide a systematic long-term identification and prevention strategy (7).

The feasibility of CPS was assessed in a large study in primary care (8). Data was gathered from lipid profile results and FH genetic analysis, obtained through a heel prick blood sample. Covering a two-year period, spanning 92 GP surgeries, the parents of 13,097 children were invited, of which 11,010 (84%) participated. The study identified 37 children carrying an FH-causing variant, suggesting a 1/273 prevalence of FH in the UK (8). A further eight children with total cholesterol (TC) over the 99<sup>th</sup> centile on repeat measures but with no mutation were also designated as having FH. The study demonstrated the feasibility and acceptability of universal screening for FH in infants. For all FH-positive children, both parents were offered referral to a FH service for pedigree analysis and cascade testing of first-degree relatives with initiation of medical management where appropriate. From this group of children, the parents of 40 were tested and 40 new adults with FH identified. Adults with FH were offered Lipid Lowering Therapy (LLT) as recommended (9) while children with FH would be given dietary and lifestyle advice, and LLT considered by the age of 10 years in line with national guidance (9) (10).

As shown in **Table 1**, we have calculated the likely frequency of HoFH in the UK, using the data from the UK study of 12-month-old infants (8), which should give an estimate unbiased by premature mortality compared to estimates if data from adult studies were used. The study of 10,000 infants (20,000 alleles) identified 15 carriers of the *APOB* p.(Arg3527Gln) variant (allele frequency 0.00075) while 22 children carried an FH-causing *LDLR* variant (allele frequency 0.0011) (8). Based on these data, and using the Hardy-Weinberg equation, it can be estimated that per million people there will 1.20 *LDLR* true homozygotes or compound heterozygotes, 0.56 *APOB* homozygotes and 1.65 *LDLR+APOB* compound heterozygotes. Overall, the prevalence of HoFH is predicted to be 3.4 per million, and for the whole of the UK (~60 million) this results in an estimate of ~200 HoFH individuals.

An alternative approach to identify children with FH would be as part of a programme to perform whole genome sequencing (WGS) as part of the proposed Newborn Genomes Programme (NGP). This has been proposed following the success of the 100,000 genomes project, which conducted a pilot study involving 4660 participants from 2183 families, who included 161 disorders covering a broad spectrum of rare diseases. Overall, a genetic diagnosis was obtained in 25% of the probands, with diagnostic yields for intellectual disability, hearing disorders, and vision disorders ranging from 40 to 55% (11). Currently the UK Newborn Screening (NBS) programme uses biochemical methods and heel-prick blood spots to screen for eight inborn errors of metabolism (Sickle cell disease [SCD], Cystic fibrosis [CF], Congenital hypothyroidism [CHT], Phenylketonuria, Medium-chain acyl-CoA dehydrogenase deficiency [MCADD], Maple syrup urine disease [MSUD], Glutaric aciduria type 1 [GAI], and Homocystinuria [HCU]). PKU, MCADD, MSUD, GAI and HCU are inherited metabolic disorders, and while some phenotypes present later (such as Homocystinuria which presents in adolescence or adulthood) requiring on-going monitoring, the infantile onset phenotypes (such as congenital hypothyroidism which presents in early childhood) need early intervention to prevent increased morbidity and mortality.

The NGP intends to carry out WGS in 100,000 newborn infants over 2 years, which should result in the identification of up to 1000 babies with these and additional inborn errors of metabolism that may require treatment in childhood. To inform the NGP steering group of which disorders should be included, four principles have been proposed, and in order to be considered for inclusion a disorder must meet all four principles. Here we set out the data to demonstrate that FH fulfils these principles.

**Principle A: There is strong evidence that the genetic variant(s) causes the condition and can be reliably detected.**

HeFH is caused by carrying a pathogenic variant in one of four different genes. In the UK, around 93% of FH patients have a pathogenic variant in the gene for the LDL-receptor (*LDLR*), ~5% have a mutation in the gene for apolipoprotein B (*APOB*) and ~2% in the gene for Proprotein Convertase Subtilisin/Kexin Type 9 (*PCSK9*) (12). Additionally, a three base pair deletion in the gene for *APOE*, which deletes an amino acid (p.(Leu167del) has also been reported to mimic the FH phenotype (13). In rare cases, a recessive inheritance pattern of elevated cholesterol is seen where the disorder may be caused by the child being homozygous for a pathogenic variant in the genes *LDLRAP1* (14) or *LIPA* (15). Homozygous FH (HoFH) is caused by inheriting two FH-causing variants, one from each HeFH parent. The Next Generation Sequencing (NGS) panels for FH currently used in the UK diagnostic Genomic Laboratory Hubs (GLHs) include all four genes. The ClinGen database currently includes *LDLR*, *APOB* and *PCSK9* as being FH causing. The ClinGen activities include developing disease-specific criteria and that for *LDLR* has already been completed (16), with similar recommendation for *APOB* and *PCSK9* being in the pipeline.

In the UK diagnostic laboratories over the last few years, from 23,855 index cases tested, 5126 were reported to have an FH-causing variant (a detection rate of 21.6%). In addition, 12,333 relatives have been tested of whom 6168 (50%) were mutation carriers (K. Haralambos personal communication). In FH testing the proportion of tests where a Variant of Uncertain Significance (VUS) is identified is low, and rigorous criteria have been developed to guide laboratories about variant calling (16), which are universally used in the UK GLHs. Of the tested index cases, 2.8% were found to carry a VUS (17), which would not be reported as part of the Newborn WGS programme.

While a DNA test for carrying an FH-causing variant is equally accurate at any age, identification of a carrier should be followed by confirmation from a blood lipid profile, and it is known that children likely to have FH already have significantly elevated cholesterol concentrations in cord blood (18)(19). Although there is an overlap in cord blood TC concentrations between infants with and without FH, measurement of the lipid profile in infants shortly after the WGS result has been obtained will be a valid biochemical measure and will discriminate well. The discrimination is better at 1 year (6)(19) so a repeat (heel-prick) measure could be performed (eg at the time of 13 month immunisation) if requested

by the parent or clinician or anytime within the first five years, during booster pre-school immunisation for example.

**Principle B: A high proportion of individuals who have the genetic variant(s) would be expected to have symptoms that would have a debilitating impact on quality of life if left undiagnosed.**

**Heterozygous FH (HeFH):** FH causes high LDL-C in the blood from birth which leads to an increased risk of early CVD. If untreated, more than 50% of men with heterozygous FH (HeFH) will develop coronary heart disease (CHD) by the age of 50 and more than 30% of women by the age of 60 (20). From both a multitude of randomised controlled intervention trials and Mendelian Randomisation studies, it is now fully accepted that there is a causal relationship between elevated LDL-C and risk of CVD, and that a high LDL-C concentration in childhood is associated with an increased risk of CVD in adulthood. Data from many longitudinal studies have documented that elevated childhood concentrations of LDL-C track through life. A recent paper from the US (21) examined whether childhood risk factors are associated with CVD in adulthood. Among 38,589 (non-FH) participants (aged 3-29 years at recruitment), over a follow up of around 35 years there were 319 fatal or non-fatal CVD events. As expected, factors such as smoking history as an adolescent, high blood pressure or body mass index were all strongly associated with future CVD risk, but having an elevated cholesterol concentration in childhood was associated with future CVD risk. The risk of CVD for those with a cholesterol concentration in the top 13% was more than twice as high as for those with a cholesterol level in the bottom 20%.

It is currently unclear what proportion of newborns found to carry an FH-causing variant will have LDL-C >3.5mmol/l by the age of 10 years, and so will qualify for initiation of statin therapy according to UK and European guidelines. One study of 1512 healthy 9-year-olds (ALSPAC) found 6 children carrying an FH-causing variant, and 5/6 (83%) had LDL-C > 3.5mmol/l (22). In the published CPS pilot study of 1 year olds, 28/37 (76%) had LDL-C >3.5mmol/l (8). However, studies have shown that carrying an FH-causing variant is associated with elevated risk of CVD even in those with relatively low LDL-C concentration. In a large study from the US (23) using NGS for the known FH genes among 20,485 CHD-free individuals, 24 (1.7%) carried an FH-causing variant. As expected, in both non-FH and FH individuals there was a clear and continuous gradient of increasing CVD risk with increasing quintiles of LDL-C concentration, but in each quintile, those carrying an FH-causing variant had markedly (2-3 fold) higher CVD risk than non-carriers. A similar relationship has been reported in healthy middle-aged men and women from the UK Biobank (24). This study compared CVD risk in 277 individuals carrying an FH-causing variant, with 2739 subjects matched for LDL-C who did not have a monogenic (or polygenic) cause for their phenotype. Compared to those with non-genetic high LDL-C, the mutation positive group had 93% higher CVD, a difference which was not changed after adjustment for LDL-C concentration (as expected since mean LDL-C concentrations in both groups was similar). This higher risk is likely

explained by the substantially higher accumulated 'LDL-C burden' in monogenic HeFH subjects, since these individuals will have had genetically-determined lifelong high LDL-C.

**Homozygous FH (HoFH):** In children, carrying two FH-causing variants or having an untreated LDL-C >13mmol/l is considered diagnostic of HoFH. Both UK (25) and European (26) guidelines recommend diagnosis of HoFH as soon as possible and immediate initiation of LLT. In HoFH, very premature life threatening asymptomatic coronary arterial disease develops within the first decade of life (25)(26). Atheroma of the aortic root associated with aortic valve fibrosis may develop before the age of 5 (27). There is also evidence that the build-up of cholesterol deposits in HoFH occurs *in utero* (28). An autopsy study of a 20 week old HoFH foetus found multifocal lipid deposition particularly involving the stromal cells of the thymus, spleen, and skin and both the stromal and parenchymal cells of the kidney. One small focus of intimal lipid accumulation was found in the aorta and coronary arteries, and the esterified cholesterol content of most tissues was 1.5 times that of a control foetus (28).

**Parallels with currently included disorders:** Two of the disorders currently included for newborn screening from blood spots have parallels with the need for monitoring and later initiation of treatment which is recommended for FH. A child with MCADD usually requires no special treatment when well, apart from avoiding prolonged fasts. These children appear clinically normal, but intercurrent illnesses or prolonged fasting can lead to severe hypoglycaemia, coma and death. MCADD is a well-recognised cause of sudden infant death (SIDS) and even coma and death. The treatment includes simple management of avoidance of fasting and additional glucose polymer drinks during illnesses to prevent hypoglycaemia. Rarely, children may remain well until later childhood or even adulthood. The mortality rate in early infantile onset MCADD could be up to 25%; and in adults, undiagnosed, this could be even up to 50% (29). Based on the risk in childhood, MCADD was first suggested for inclusion in the mid 90's and was finally included in the Newborn Screening (NBS) Programme in 2003. The situation with PKU also has parallels with FH. Treatment consists of restriction of phenylalanine from the early neonatal period. Without early identification in the newborn and early intervention, babies with PKU will develop catastrophic cognitive impairment. However, in some cases babies are identified by NBS with hyperphenylalaninaemia, and these infants may not require strict dietary intervention daily but may need it during intercurrent illness. These examples highlight that not all children identified by the current NBS have an acute urgent life threatening clinical presentation.

The need for early detection of FH is supported by many patient charities in the UK (the British Heart Foundation (BHF) and HEART-UK) and in Europe and the US (30)(31). The HEART-UK website (<https://www.heartuk.org.uk/>) contains many videos and testimonials about the impact on a family of the sudden death of a relative due to CHD, and their positive view of systematic testing of relatives and children to identify at-risk individuals before they develop coronary symptoms.

**Principle C: Early or pre-symptomatic intervention for the condition has been shown to lead to substantially improved outcomes in children, compared to intervention after the onset of symptoms.**

**Heterozygous FH:** The UK 2008/2017 NICE Guideline (9) on the management of FH contains 16 recommendations specifically targeted to the management of paediatric HeFH. These formed the basis of the HEART UK Statement of Care (SoC) (10), and there is good uniformity among UK Paediatricians treating FH. The SoC recommends that children diagnosed with mutation-positive HeFH are seen by a paediatric FH specialist, advice given on healthy lifestyle throughout childhood and an individual care plan established. Dietary and lifestyle advice should include the whole family and age appropriate national guidance followed for healthy eating and calorie intake for children.

Annual follow up from the age of 8 years is recommended to reassess the lipid profile and consider statin initiation by the age of 10 years if LDL-C >3.5mmol/L. In the UK Paediatric FH Register, more than 95% of children with HeFH had LDL-C above this threshold (32). NICE guidance and clinical practice also takes into account the age of onset of CHD in the family and the presence of other cardiovascular risk factors in the child. These UK guidelines are similar to those proposed by the European Atherosclerosis Society (33).

There are three different ways that early identification of a child with HeFH will lead to improved outcomes for the child.

**Short-term benefit from adopting a healthy lifestyle:** All UK and European guidelines recommend healthy diet and lifestyle for the management of children with HeFH. Dietary intervention with a low saturated fat diet has been shown in a randomized trial to result in a healthier diet and lower LDL-C levels in both adults and children with HeFH (34). Early dietary intervention benefits the whole family and particularly children, whose dietary and lifestyle choices are developing, and can be established for life (35). The UK Paediatric Register has reported that significantly fewer children with HeFH are overweight or obese than age-matched UK general population children (36).

**Intermediate-term benefit from the identification of their HeFH parent:** The method of screening at birth and identifying children with FH will allow timely cascade testing of parents and relatives. One parent of any child with an HeFH diagnosis will also be affected, and once identified stands to benefit from immediate statin treatment, reducing their future risk of early CHD and death from Myocardial Infarction. Several studies have reported that parentally bereaved children are at increased risk for mental health problems as they grow up, including depression, anxiety, and behaviour problems (37)(38). Children in single parent families may also show poorer educational achievement (39)(40). In a study from three Nordic countries (41), parental death before the child was 18 years old was associated with a 50% increased all-cause mortality over around 30 years of follow up, an effect that was independent of age at bereavement.

**Long-term benefit from reduction in their risk of early CVD:** HeFH causes high cholesterol in the blood from birth and this leads to increased risk of early heart disease and stroke. Data from UK Biobank has shown carriers of an FH-causing variant have considerably earlier onset of CHD, even when adjusting for their elevated LDL-C (24). The UK (Simon Broome) FH Register has shown that if untreated, more than 50% of men with HeFH will develop CHD by the age of 50 and more than 30% of women by the age of 60 (20). However, the Register data also shows that life expectancy for HeFH patients is restored to near normal with early preventive treatment, particularly using high intensity statins (42) and ezetimibe. The new generation of LLTs available that block PCSK9 activity (43) can help achieve even lower LDL-C concentrations, and risk CVD reductions are likely to be even larger.

As shown in **Figure 1**, because of their rapidly increasing LDL-C Burden (44), atherosclerosis develops early in children with HeFH. Studies using ultrasound of the carotid artery as a surrogate measure of the development of atherosclerosis have shown that by the age of 10 years, the mean Carotid intima-Media thickness (CIMT) of children with FH is significantly greater than that of their non-FH siblings (45) and if treated with statin LLT this thickness declines over two years (46). These data were the evidence on which NICE and HEART-UK guidelines recommend consideration of statin initiation by the age of 10 years (9)(10). Taking into account the concept of LDL-C Burden, early identification improves the cost effectiveness of the screening (47).

The long-term safety of statin therapy started in childhood is an important issue. The accumulating data in children with FH supports the view that statin treatment from the age of 10 years has no short- or long-term adverse effects on growth or transition through puberty, and only rarely has any side effects, such as liver dysfunction and muscle pains, which are usually minimal (48). These safety data are supported by findings from the UK FH Children's Register(19). One recent study found no long-term safety issues after 20 years of follow-up and clear benefit in reduction of CHD events (49).

**Homozygous FH (HoFH):** As shown in **Figure 1**, because of their rapidly increasing LDL-C Burden, atherosclerosis develops early in children with HoFH, and by the age of 12-13 years their LDL-C burden is equivalent to that of a 55 year old non-FH individual. Survival analysis in patients with HoFH before and after the introduction of statins showed considerable reduction in CVD events and deaths (50). Prescription of drugs beyond licence is recommended in the context of a multidisciplinary team meeting. Initiation of LDL-apheresis is recommended from the age of 5 years if the LDL-C target of >3.5mmol/l is not achieved (25,26). While statins remain the first group of medications to be considered, additional agents are now being used in young people with FH, including PCSK9 inhibitors. Evolocumab is licensed from the age of 12. The TAUSSIG trial (51), a long-term open label study of treatment of HoFH patients with evolocumab has studied 106 patients, including 14 adolescents. LDL-C lowering was influenced by genotype, for example mean reductions were -24% for LDLR defective, but only 6% for LDLR negative/negative patients. New agents such



as inhibitors of ANGPTL3 have been shown to be effective in HoFH (52) (53), as well as the currently licensed MTP inhibitor Lomitapide used in adults (54).

**Principle D: Conditions screened for are only those for which the interventions are equitably accessible for all.**

**Heterozygous FH:** Triage, diagnosis and management of FH is largely managed through specialist lipid clinics. Services in the England and the Devolved countries are well placed to manage children and family members diagnosed with FH through a newborn WGS screening programme. HEART-UK has published a Statement of Care for children with HeFH (10) based on NICE (9) (9) and European Guidelines (26) which outlines the ideal care pathway for children with FH. These guidelines recommend that children with FH should be referred to and managed by a clinician with expertise in managing children with FH ie a Paediatrician. In recent years there has been considerable investment to develop FH patient care pathways in the UK, with the HEART-UK website (<https://www.heartuk.org.uk/>) identifying a network of over 100 clinics managing adults with FH and over 60 offering paediatric care. These have adequate capacity to manage the additional children and parents with FH identified through this programme. Currently we do not have data to indicate whether it would be necessary to use different cut-offs for statin initiation in different ethnicities, and the >3.5mmol/l is recommended for all ethnic groups.

As well as a national coverage of FH nurses who area already treating patients, training is also being delivered to general practice staff, GPs, Nurses, Pharmacists on how to deliver news of diagnosis and how to counsel parents (55) (56). Treatment of children with FH will not be done by GPs and pathways for children that are diagnosed through the NGP will follow the NICE established pathway as outlined (9) (10).

**Homozygous FH (HoFH):** With an annual rate of ~700,000 live births, over the 2-year period of the NGP there are likely to be 1.7 *LDLR* true homozygotes or compound heterozygotes, 0.8 *APOB* homozygotes and 2.3 *LDLR+APOB* compound heterozygotes born in the UK. Since there is high consanguinity in some ethnic groups this overall figure of ~5 HoFH newborns over 2 years may be higher. However, since the NGP pilot will initially examine 100,000 infants there is likely to be less than one HoFH child identified in the programme. There are currently 7 centres in the UK that offer apheresis (57), who will be able to offer this treatment to any identified child when appropriate.

## **Conclusion**

FH meets all the Wilson and Jungner criteria for screening (58) as well as all four of the principles that are required for a disorder to be included in the Newborn WGS pilot. Whilst lipid lowering therapies are considered by the age of 10 years in children with HeH, early education on a healthy diet and lifestyle choices, including avoidance of smoking, are very

important in the overall management. Early identification of Homozygous FH, by newborn WGS, would result in early identification and treatment. For each HeFH child, the HeFH parent could be identified before a major CVD event and started on lipid lowering therapies. If newborn whole genome sequencing does include FH, the Child-Parent Screening program based on cholesterol measurement at the 12month time of immunisation would no longer be required. Identification of infants with FH by WGS is superior to the CPS protocol since all carriers of an FH-causing variant will be identified, but in the published pilot study (8), only 54% of the children carrying an FH causing variant had a TC > 95<sup>th</sup> centile, meaning 46% of mutation carriers would potentially be missed.

Based on the estimated ~1/290 prevalence of FH in the UK (3) we would predict less than one child with HoFH and around 350 children with HeFH-causing variant will be identified, which would lead to the identification of an additional ~350 parents with HeFH and through cascade testing more than 700 HeFH siblings, and second-degree relatives. Lifestyle modification and LLT offered when age appropriate would significantly reduce future CVD risk of these individuals, and the current NHS adult and paediatric lipid clinic infrastructure will be able to cope with this number of patients. Detailed economic modelling has not been performed, but published data (on screening at 1 year) suggests that this programme would be highly cost effective (59), and that any anxiety caused by receiving an FH DNA test is minimal (60). This potential future universal genomics-based screening approach would circumvent the myriad problems of trying to identify FH using biochemical and clinical tests, allow early interventions as appropriate for the child and parent(s) and would also remove the burden to the child, family and NHS of using a child-parent screening approach at 12 months.

## **DECLARATIONS**

**Acknowledgments/Funding:** SEH is an Emeritus BHF Professor and acknowledges funding from the British Heart Foundation (BHF) (RG08/008), and the National Institute for Health Research and University College London Hospitals Biomedical Research Centre. The Paediatric FH Register has been previously supported by funds from the BHF, HEART UK, Cardiac Network Co-ordinating Group Wales, The Royal College of Physicians, and a grant from the International Society of Atherosclerosis (Pfizer number 24052829).

**Conflict of Interest:** SEH is the Medical Director of a UCL Spin-off company (StoreGene) that offers genetic testing for cardiovascular risk including for FH. SEH also reports payment for expert testimony from Verve Therapeutics (to self), and support from the European Atherosclerosis Society to attend EAS 2022 in Milan, and 2023 in Mannheim. UR has received advisory board fees from Esperion, and has no conflicts of interest related to this manuscript. NH has no conflicts of interest to declare.

**Human and Animal Rights and Informed Consent:** This article does not contain any studies with human or animal subjects performed by any of the authors.

## References:

Papers of particular interest, published recently, have been highlighted as:

- Of importance
- Of major importance

1. Marks D, Thorogood M, Neil HAW, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. *Atherosclerosis*. 2003 May;168(1):1–14.
2. Akioyamen LE, Genest J, Shan SD, Reel RL, Albaum JM, Chu A, et al. Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. *BMJ Open*. 2017 Sep 1;7(9):e016461.
3. \*\*Gratton J, Humphries SE, Futema M. Prevalence of FH-Causing Variants and Impact on LDL-C Concentration in European, South Asian, and African Ancestry Groups of the UK Biobank-Brief Report. *Arterioscler Thromb Vasc Biol*. 2023 Sep;43(9):1737–42.

The study included 140 439 European, 4067 South Asian, and 3906 African participants in the UK BioBank. No statistical difference in the prevalence of an FH-causing variant was observed (1/288 in European, 1/260 in African, and 1/226 in South Asian. Carriers of an FH-causing variant had significantly higher LDL-C concentration than noncarriers in every ancestry group. There was no difference in mean (statin-use adjusted) LDL-C concentration in FH-variant carriers depending on their ancestry background.

4. NHS England. NHS Long Term Plan [Internet] 2019 [cited 2022 Nov 24] Available at <https://www.longtermplan.nhs.uk/wp-content/uploads/2019/01/nhs-long-term-plan.pdf>.
5. Kerr M, Pears R, Miedzybrodzka Z, Haralambos K, Cather M, Watson M, et al. Cost effectiveness of cascade testing for familial hypercholesterolaemia, based on data from familial hypercholesterolaemia services in the UK. *Eur Heart J*. 2017 Jun 14;38(23):1832–9.
6. Wald DS, Bestwick JP, Wald NJ. Child-parent screening for familial hypercholesterolaemia: screening strategy based on a meta-analysis. *BMJ*. 2007 Sep 22;335(7620):599.
7. Wald DS, Bestwick JP. Reaching detection targets in familial hypercholesterolaemia: Comparison of identification strategies. *Atherosclerosis*. 2020 Jan;293:57–61.
8. Wald DS, Bestwick JP, Morris JK, Whyte K, Jenkins L, Wald NJ. Child-Parent Familial Hypercholesterolemia Screening in Primary Care. *N Engl J Med*. 2016 Oct 27;375(17):1628–37.
9. National Institute for Health and Care Excellence. Familial hypercholesterolaemia: identification and management National Institute for Health and Care Excellence. NICE

clinical guideline (CG71) [internet] 2008 [cited 2022 Nov 24]. Available from: <https://www.nice.org.uk/guidance/cg71>.

10. Ramaswami U, Humphries SE, Priestley-Barnham L, Green P, Wald DS, Capps N, et al. Current management of children and young people with heterozygous familial hypercholesterolaemia - HEART UK statement of care. *Atherosclerosis*. 2019 Nov;290:1–8.
11. \*100,000 Genomes Project Pilot Investigators, Smedley D, Smith KR, Martin A, Thomas EA, McDonagh EM, et al. 100,000 Genomes Pilot on Rare-Disease Diagnosis in Health Care - Preliminary Report. *N Engl J Med*. 2021 Nov 11;385(20):1868–80.

The Study involved 4660 participants from 2183 families, who included 161 disorders covering a broad spectrum of rare diseases. Overall a genetic diagnosis was obtained in 25% of the probands, with diagnostic yields for intellectual disability, hearing disorders, and vision disorders ranging from 40 to 55%

12. Humphries SE, Whittall RA, Hubbart CS, Maplebeck S, Cooper JA, Soutar AK, et al. Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. *J Med Genet*. 2006 Dec;43(12):943–9.
13. Marduel M, Ouguerram K, Serre V, Bonnefont-Rousselot D, Marques-Pinheiro A, Erik Berge K, et al. Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation. *Hum Mutat*. 2013 Jan;34(1):83–7.
14. Soutar AK, Naoumova RP. Autosomal recessive hypercholesterolemia. *Semin Vasc Med*. 2004 Aug;4(3):241–8.
15. Stitzel NO, Fouchier SW, Sjouke B, Peloso GM, Moscoso AM, Auer PL, et al. Exome sequencing and directed clinical phenotyping diagnose cholesterol ester storage disease presenting as autosomal recessive hypercholesterolemia. *Arterioscler Thromb Vasc Biol*. 2013 Dec;33(12):2909–14.
16. Chora JR, Iacocca MA, Tichý L, Wand H, Kurtz CL, Zimmermann H, et al. The Clinical Genome Resource (ClinGen) Familial Hypercholesterolemia Variant Curation Expert Panel consensus guidelines for LDLR variant classification. *Genet Med Off J Am Coll Med Genet*. 2022 Feb;24(2):293–306.
17. Haralambos K, Payne J, Datta D, McDowell I, Cramb R, Williams S, Cather M, Neely D, Soran H, Miedzybrodzka Z, Whitmore J. How many patients with a monogenic diagnosis of Familial Hypercholesterolemia are currently known in UK lipid clinics?. *Atherosclerosis Supplements*. 2017 Sep 1;28:e8-9.
18. Kwiterovich PO, Levy RI, Fredrickson DS. Neonatal diagnosis of familial type-II hyperlipoproteinaemia. *Lancet Lond Engl*. 1973 Jan 20;1(7795):118–21.

19. Vuorio AF, Turtola H, Kontula K. Neonatal diagnosis of familial hypercholesterolemia in newborns born to a parent with a molecularly defined heterozygous familial hypercholesterolemia. *Arterioscler Thromb Vasc Biol.* 1997 Nov;17(11):3332–7.
20. Scientific Steering Committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. *Atherosclerosis* 1999;142:105.
21. \*Jacobs DR, Woo JG, Sinaiko AR, Daniels SR, Ikonen J, Juonala M, et al. Childhood Cardiovascular Risk Factors and Adult Cardiovascular Events. *N Engl J Med.* 2022 May 19;386(20):1877–88.

Among 38,589 participants (3-29 years at recruitment), over a follow up of ~35 years there were 319 fatal or non-fatal CVD events. Smoking history as an adolescent, high blood pressure or body mass index were all strongly associated with future CVD risk. The risk of CVD for those with a cholesterol concentration in the top 13% was more than twice as high as for those with a cholesterol level in the bottom 20%.

22. Futema M, Cooper JA, Charakida M, Boustred C, Sattar N, Deanfield J, et al. Screening for familial hypercholesterolaemia in childhood: Avon Longitudinal Study of Parents and Children (ALSPAC). *Atherosclerosis.* 2017 May;260:47–55.
23. Khera AV, Won HH, Peloso GM, Lawson KS, Bartz TM, Deng X, et al. Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. *J Am Coll Cardiol.* 2016 Jun 7;67(22):2578–89.
24. Trinder M, Francis GA, Brunham LR. Association of Monogenic vs Polygenic Hypercholesterolemia With Risk of Atherosclerotic Cardiovascular Disease. *JAMA Cardiol.* 2020 Apr 1;5(4):390–9.
25. France M, Rees A, Datta D, Thompson G, Capps N, Ferns G, et al. HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom. *Atherosclerosis.* 2016 Dec;255:128–39.
26. \*\*Cuchel M, Raal FJ, Hegele RA, Al-Rasadi K, Arca M, Averna M, et al. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance. *Eur Heart J.* 2023 Jul 1;44(25):2277–91.

New guidelines include updated criteria for the clinical diagnosis of HoFH and the recommendation to prioritize phenotypic features over genotype. Having LDL-C >0 mmol/L (>400 mg/dL) is suggestive of HoFH and warrants further evaluation. Provides state-of-the art discussion and guidance to clinicians for interpreting the results of genetic testing and for family planning and pregnancy.

27. Rallidis L, Nihoyannopoulos P, Thompson GR. Aortic stenosis in homozygous familial hypercholesterolaemia. *Heart Br Card Soc.* 1996 Jul;76(1):84–5.
28. Buja LM, Kovanen PT, Bilheimer DW. Cellular pathology of homozygous familial hypercholesterolemia. *Am J Pathol.* 1979 Nov;97(2):327–57.
29. Lang TF. Adult presentations of medium-chain acyl-CoA dehydrogenase deficiency (MCADD). *J Inherit Metab Dis.* 2009 Dec;32(6):675–83.
30. \*\*Gidding SS, Wiegman A, Groselj U, Freiburger T, Peretti N, Dharmayat KI, et al. Paediatric familial hypercholesterolaemia screening in Europe: public policy background and recommendations. *Eur J Prev Cardiol.* 2022 Dec 21;29(18):2301–11.

Recommendations are presented aiming to improve identification of FH and emphasize that every country should have an FH screening programme. These programmes should be adapted from existing strategies to best fit the individual country's healthcare system, governments should provide financial support for these programmes and related care. Further research is recommended to optimize care and implementations.

31. \*\*Watts GF, Gidding SS, Hegele RA, Raal FJ, Sturm AC, Jones LK, et al. International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia. *Nat Rev Cardiol.* 2023 Jun 15;

a group of international experts systematically developed this guidance for the detection and management of adults or children with heterozygous or homozygous FH, including therapy during pregnancy and use of apheresis. It updates clinical recommendations, and proposes consensus-based implementation strategies with the aim of maximizing the potential benefit for at-risk patients and their families worldwide.

32. Ramaswami U, Cooper J, Humphries SE, FH Paediatric Register Steering Group. The UK Paediatric Familial Hypercholesterolaemia Register: preliminary data. *Arch Dis Child.* 2017 Mar;102(3):255–60.
33. Wiegman A, Gidding SS, Watts GF, Chapman MJ, Ginsberg HN, Cuchel M, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. *Eur Heart J.* 2015 Sep 21;36(36):2425–37.
34. \*Kinnear FJ, Lithander FE, Searle A, Bayly G, Wei C, Stensel DJ, et al. Reducing cardiovascular disease risk among families with familial hypercholesterolaemia by improving diet and physical activity: a randomised controlled feasibility trial. *BMJ Open.* 2020 Dec 28;10(12):e044200.

Study recruited 22 children and 17 adults with FH, who were randomised to either 12-week usual care or intervention aimed to improve dietary, physical activity and

sedentary behaviours. Intervention was associated with improvements in several CVD risk factors including LDL-C, with a within-group mean decrease of 8% (children) and 10% (adults).

35. Matthews LA, Rovio SP, Jaakkola JM, Niinikoski H, Lagström H, Jula A, et al. Longitudinal effect of 20-year infancy-onset dietary intervention on food consumption and nutrient intake: the randomized controlled STRIP study. *Eur J Clin Nutr.* 2019 Jun;73(6):937–49.
36. Humphries SE, Cooper J, Dale P, Ramaswami U, FH Paediatric Register Steering Group. The UK Paediatric Familial Hypercholesterolaemia Register: Statin-related safety and 1-year growth data. *J Clin Lipidol.* 2018;12(1):25–32.
37. JR Ayers, TS Sandler, Sandley IN, Barr A. JR, Ayers TS, Sandler IN, Barr A. Risks and interventions for the parentally bereaved child. In *Handbook of children's coping 1997* (pp. 215-243). Springer, Boston, MA. In.
38. Melhem NM, Moritz G, Walker M, Shear MK, Brent D. Phenomenology and correlates of complicated grief in children and adolescents. *J Am Acad Child Adolesc Psychiatry.* 2007 Apr;46(4):493–9.
39. Mikkonen HM, Salonen MK, Häkkinen A, Olkkola M, Pesonen AK, Räikkönen K, et al. The lifelong socioeconomic disadvantage of single-mother background - the Helsinki Birth Cohort study 1934-1944. *BMC Public Health.* 2016 Aug 18;16(1):817.
40. Hampden-Thompson G. Family policy, family structure, and children's educational achievement. *Soc Sci Res.* 2013 May;42(3):804–17.
41. Li J, Vestergaard M, Cnattingius S, Gissler M, Bech BH, Obel C, et al. Mortality after parental death in childhood: a nationwide cohort study from three Nordic countries. *PLoS Med.* 2014 Jul;11(7):e1001679.
42. Humphries SE, Cooper JA, Seed M, Capps N, Durrington PN, Jones B, et al. Coronary heart disease mortality in treated familial hypercholesterolaemia: Update of the UK Simon Broome FH register. *Atherosclerosis.* 2018 Jul;274:41–6.
43. Page MM, Watts GF. Emerging PCSK9 inhibitors for treating dyslipidaemia: buttressing the gaps in coronary prevention. *Expert Opin Emerg Drugs.* 2015 Jun;20(2):299–312.
44. Vuorio A, Docherty KF, Humphries SE, Kuoppala J, Kovanen PT. Statin treatment of children with familial hypercholesterolemia--trying to balance incomplete evidence of long-term safety and clinical accountability: are we approaching a consensus? *Atherosclerosis.* 2013 Feb;226(2):315–20.
45. Wiegman A, de Groot E, Hutten BA, Rodenburg J, Gort J, Bakker HD, et al. Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. *Lancet Lond Engl.* 2004 Jan 31;363(9406):369–70.

46. Wiegman A, Hutten BA, de Groot E, Rodenburg J, Bakker HD, Büller HR, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. *JAMA*. 2004 Jul 21;292(3):331–7.

47. \*Faria R, Saramago P, Cox E, Weng S, Iyen B, Akyea RK, et al. How does cholesterol burden change the case for investing in familial hypercholesterolaemia? A cost-effectiveness analysis. *Atherosclerosis*. 2023 Feb;367:40–7.

A UK-NHS cost-effectiveness model was developed for individuals with FH. The primary outcome was net health gain expressed in quality-adjusted life years (QALYs). Prognostic factors included pre-treatment LDL-C, age, gender, and CVD history. Authors found that if cholesterol burden was considered, diagnosis resulted in positive net health gain (i.e., it is cost-effective) in all individuals with pre-treatment LDL-C  $\geq 4$  mmol/L, and in those with pre-treatment LDL-C  $\geq 2$  mmol/L aged  $\geq 50$  years or who have CVD history.

48. Vuorio A, Kuoppala J, Kovanen PT, Humphries SE, Tonstad S, Wiegman A, et al. Statins for children with familial hypercholesterolemia. *Cochrane Database Syst Rev*. 2017 Jul 7;7(7):CD006401.

49. \*\*Luirink IK, Wiegman A, Kusters DM, Hof MH, Groothoff JW, de Groot E, et al. 20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia. *N Engl J Med*. 2019 Oct 17;381(16):1547–56.

184 patients with HeFH and 77 siblings were seen after 20 years of follow-up. The mean LDL-C level was 32% lower than baseline level. Mean progression of carotid intima-media thickness over the entire follow-up period was not different in FH vs siblings. The cumulative incidence of cardiovascular events and of death from cardiovascular causes at 39 years of age was lower among the patients with FH than among their affected parents.

50. Thompson GR, Blom DJ, Marais AD, Seed M, Pilcher GJ, Raal FJ. Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol. *Eur Heart J*. 2018 Apr 7;39(14):1162–8.

51. Raal FJ, Hovingh GK, Blom D, Santos RD, Harada-Shiba M, Bruckert E, et al. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. *Lancet Diabetes Endocrinol*. 2017 Apr;5(4):280–90.

52. Gaudet D, Gipe DA, Pordy R, Ahmad Z, Cuchel M, Shah PK, et al. ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia. *N Engl J Med*. 2017 Jul 20;377(3):296–7.

53. \*Reeskamp LF, Millar JS, Wu L, Jansen H, van Harskamp D, Schierbeek H, et al. ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients



With Homozygous Familial Hypercholesterolemia-Brief Report. *Arterioscler Thromb Vasc Biol.* 2021 May 5;41(5):1753–9.

Four patients with HoFH underwent apoB kinetic as part of a trial evaluating the efficacy and safety of evinacumab. Evinacumab lowered LDL-C by 59±2% and increased IDL apoB and LDL apoB fractional catabolic rate in all 4 homozygous familial hypercholesterolemia subjects.

54. Blom DJ, Aversa MR, Meagher EA, du Toit Theron H, Sirtori CR, Hegele RA, et al. Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholesterolemia. *Circulation.* 2017 Jul 18;136(3):332–5.
55. <https://www.genomicseducation.hee.nhs.uk/about-us/supporting-the-national-transformation-projects/transformation-project-familial-hypercholesterolaemia/>.
56. <https://elearning.rcgp.org.uk/course/info.php?id=487>](<https://elearning.rcgp.org.uk/course/info.php?id=487>).
57. Pottle A, Thompson G, Barbir M, Bayly G, Cegla J, Cramb R, et al. Lipoprotein apheresis efficacy, challenges and outcomes: A descriptive analysis from the UK Lipoprotein Apheresis Registry, 1989-2017. *Atherosclerosis.* 2019 Nov;290:44–51.
58. Wilson JM, Jungner G, World Health Organization. Principles and practice of screening for disease. WHO papers No 34.;1968.
59. McKay AJ, Hogan H, Humphries SE, Marks D, Ray KK, Miners A. Universal screening at age 1-2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis. *Atherosclerosis.* 2018 Aug;275:434–43.
60. Marteau T, Senior V, Humphries SE, Bobrow M, Cranston T, Crook MA, et al. Psychological impact of genetic testing for familial hypercholesterolemia within a previously aware population: a randomized controlled trial. *Am J Med Genet A.* 2004 Jul 30;128A(3):285–93.

**Table 1. Shows the predicted number of homozygous *LDLR*, *APOB* and compound heterozygous individuals in UK (based on allele frequency in [8])**

<b>FH-causing gene</b>	<b>Wald data<sup>1</sup> [95%CI]</b>	<b>Allele frequency [95%CI]</b>	<b>Number homozygotes/ million [95%CI]<sup>2</sup></b>	<b>Number expected in UK (~60million) [95%CI]</b>
<b>LDLR (any)</b>	22/20,000 [14 – 33]	0.0011 [0.0007-0.00165]	1.20 <sup>2</sup> [0.49 - 2.7]	72 <sup>2</sup> [29.4 - 162]
<b>APOB p.(Arg3527Gln)</b>	15/20,000 [8 - 25]	0.00075 [0.0004-0.00125]	0.56 [0.16 – 1.56]	33.6 [9.6 - 93.6]
<b>LDLR + APOB compound Homozygotes</b>	NA	NA	1.65 [0.56 - 4.13]	99 [33.6 - 248]
<b>Total</b>	37/20,000 [25-49]	0.00185 [0.00125-0.00245]	3.4 [1.28 - 8.4]	204 [76.8 - 504]


<sup>1</sup>10,000 children = 20,000 alleles.

<sup>2</sup>Includes both true homozygotes and compound heterozygotes.

The frequency of homozygous *LDLR* and *APOB* FH individuals and for those compound heterozygous for both an *LDLR* and *APOB* was estimated using an expansion of the Hardy-Weinberg equation,  $p^2 + 2pq + q^2 + 2pr + 2rq + r^2 = 1$ , where p = the frequency of the common allele at the locus (wild type), q = the frequency of the *LDLR* FH-causing rare allele, and r = the frequency of the *APOB* FH-causing rare allele (p.(Arg3527Gln).

95% Confidence intervals were estimated using a standard binomial “exact” calculations.

Figure 1.



**Figure 1. LDL cholesterol (LDL-C) burden in non-FH and FH subjects depending on different age of starting statin therapy.** The LDL-C burden is calculated as the sum of the current LDL-C concentration x age in years. The cumulative LDL-C burden of a 55-year-old non-FH patient is 160 mmol, and it has been reached by an individual with HoFH by the age of 12.5 years, by an untreated-FH patient by the age of 35 years, by an FH patient treated since age 18 years by the age of 48 years, and by an FH patient treated since age of 10 years by the age of 53 years. (From: Vuorio A, et al. *Atherosclerosis*. 2013 Feb;226(2):315–20, with permission from Elsevier) [44].